[Neoadjuvant chemoradiotherapy versus neoadjuvant chemo-immunotherapy for locally advanced esophageal squamous cell carcinoma].

Xiaoxuan Wang、Hongxing Shen、R H Li、Jialin Wang、Meiyu Fang、Kaiyi Tao、Yanlian Jiang、Yuan Ji

2024PubMedMedicine被引 3

摘要

These results suggest that nCIT could significantly improve disease-free survival rate and overall survival rate over nCRT in locally advanced ESCC, even with lower pathological complete response rate.

引用本文（GB/T 7714）

Xiaoxuan Wang, Hongxing Shen, R H Li, 等. [Neoadjuvant chemoradiotherapy versus neoadjuvant chemo-immunotherapy for locally advanced esophageal squamous cell carcinoma].[J]. PubMed, 2024.

引文网络

参考文献与被引分析加载中…

DOI：https://doi.org/10.3760/cma.j.cn112152-20240503-00180

本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。